Abstract Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating disease of the brain caused by the JC virus that occurs mainly in immunocompromised patients. The prognosis is very poor. As the lesion looks like non-specific leukoencephalopathy, making a diagnosis at the early stage is very difficult. We report three PML cases in which there was a mismatch between 11 C-methionine-positron emission tomography (MET-PET) uptake and 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) uptake. All three cases demonstrated the hyper-uptake of MET around the white matter lesions and hypo-uptake of FDG inside the lesions. We speculate that the infection had ended inside the white matter lesions of these patients, while JC virus infection was ongoing around the lesions, resulting in the increase of methionine metabolism, and the glucose metabolism was reduced or intermediate because inflammatory cells infiltrate PML lesions rarely. Two patients who were diagnosed and treated with mefloquine while the JC virus was at a low level in the cerebrospinal fluid are still alive. We suggest the usefulness of MET-PET for the early diagnosis of PML and early treatment with mefloquine.
Introduction
Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating disease of the brain caused by the JC virus (JCV) and occurs mainly in immunocompromised patients. The prognosis is very poor. As the lesion resembles non-specific leukoencephalopathy, it is difficult to make a diagnosis at the early stage of the disease. We report three PML cases in which there was a mismatch between 11 C-methionine-positron emission tomography (MET-PET) uptake and 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) uptake in and around the lesions. We suggest this mismatch may be useful for the early diagnosis of PML.
Subjects and methods

Case series
We report three PML cases without human immunodeficiency virus (HIV) infection from July 2012 to December 2013.
Case 1
A 51-year-old man was admitted to our hospital in July 2012 because of gait impairment. He reported dizziness and gait impairment from April 2012, when he was followed for chronic hepatitis B infection and hepatic cell carcinoma. Ataxia of the four extremities was detected and a cerebellar lesion was observed on magnetic resonance imaging (MRI). His positive neurological findings were slurred speech, left spastic hemiparesis (MMT 4), and ataxia of the four extremities. He could not stand by himself. He had a slight hepatic function disorder and was positive for the hepatitis B virus surface (HBs) and hepatitis B virus e (HBe) antigens. Hepatitis C virus (HCV) and HIV antibodies were negative. His cerebrospinal fluid (CSF) showed a cell count of 2 cells/lL, protein level of 27 mg/dL, and glucose level of 60 mg/dL. The polymerase chain reaction (PCR) for JCV was negative. A brain biopsy from the left middle cerebellar peduncle resulted in a diagnosis of glioma. The pathological findings revealed swollen oligodendrocytes on hematoxylin-eosin staining, demyelination on Klüver-Barrera staining, and staining using anti-agnoprotein and anti-VP1 antibodies was positive, which was consistent with PML ( Fig. 1a-d) . Mefloquine therapy was initiated. His symptoms improved and he was able to ride in a wheelchair in December 2013.
Case 2
An 80-year-old male was admitted to our hospital because of right hemiparesis, aphasia, and dysarthria. He underwent chemotherapy including rituximab for primary thyroid MALT lymphoma in June 2011. He had slight weakness of his right upper and lower extremities in October 2012. His symptoms worsened and a brain MRI showed white matter lesions of the right frontal and parietal lobes. He was admitted to our hospital in February 2013 because the white matter lesion enlarged and his symptoms worsened further.
His positive neurological findings on admission were motor aphasia, right unilateral spatial neglect, dysphagia, and right hemiparesis. He had a slight elevation of serum soluble interleukin 2 (IL-2) receptor (654 U/mL). He was negative for the HBs antigen and HCV and HIV antibodies. His CSF showed a cell count of\1 cell/lL, protein level of 31 mg/dL, and glucose level of 85 mg/dL. He was diagnosed as probable PML because PCR for JCV in the CSF was positive (5.08 9 10 5 copies/mL). Although mefloquine therapy was initiated, his symptoms worsened and the amount of JCV in the CSF increased to 5.91 9 10 6 copies/mL. He died on the 97th hospital day. 
Methods
In addition to brain MRI and FDG-PET, we assessed the MET-PET findings of each case, which have been used to evaluate low-grade glioma and cerebral inflammatory lesions [1, 2] . The MET-PET images were acquired with an EXACT HR ? scanner (Asahi-Siemens Medical Technologies LTD., Tokyo, Japan). 
Results
Case 1
Brain MRI showed a left middle cerebellar peduncle lesion (Fig. 2a) . FDG-PET showed low uptake inside the lesion (Fig. 2b) and MET-PET showed hyper-uptake around the lesion (Fig. 2c) .
Case 2
Brain MRI showed leukoencephalopathy in the white matter of the left parietal lobe (Fig. 2d) . FDG-PET showed low uptake inside the lesion (Fig. 2e) and MET-PET showed hyper-uptake around the lesion (Fig. 2f) .
Case 3
Brain MRI showed leukoencephalopathy in the white matter of the right frontal and parietal lobes (Fig. 2g) . FDG-PET showed low uptake inside the lesion (Fig. 2h) and MET-PET showed hyper-uptake around the lesion (Fig. 2i) . After treatment was initiated, the white matter lesion enlarged on brain MRI (Fig. 2j) and FDG-PET (Fig. 2k) . However, the hyper-uptake of methionine decreased (Fig. 2l) .
Discussion
Progressive multifocal leukoencephalopathy is an infectious multifocal demyelinating disease of the brain caused by JCV infection of oligodendrocytes. No definitive treatment has been established, so the prognosis is very poor. The underlying disorders are various, such as HIV infections, hematopoietic neoplasms, autoimmune diseases, and monoclonal antibodies [3] . Nowadays, the number of monoclonal antibodies related to PML, such as in case 2, is increasing. Especially, neurologists are aware of the risk of PML when immunosuppressive therapy including natalizumab is used to treat multiple sclerosis [4] . Cases in which mefloquine therapy was effective have been reported [5, 6] .
A summary of our three cases is presented in Table 1 . In the surviving cases, we were able to initiate mefloquine therapy when the amount of JCV in the CSF was low.
All three cases indicated the hyper-uptake of MET around the white matter lesions and hypo-uptake of FDG inside the lesions. Only one case report from Japan has described the hyper-uptake of MET in a patient with PML [7] . We suggest that the infection had ended inside the white matter lesions of our cases, while JCV infection was ongoing around the lesions, resulting in the increase of methionine metabolism, and glucose metabolism was reduced or intermediate because inflammatory cells infiltrate PML lesions rarely. In case 3, only the MET-PET abnormality improved after treatment. We hypothesize that the degeneration might have ended in the areas where methionine uptake was increased, so the T2 intensity increased. Moreover, methionine uptake was prevented and PCR for JCV in the CSF was negative. We could not follow up the PET findings of the treated patient (case 1) and the untreated patient (case 2), which is a limitation of this study. We speculate that the reduction of the amount of JCV in case 3 resulted in the improvement of the MET-PET findings.
We reported 3 cases of PML without HIV infection. The neurological impairments of such patients may improve when the amount of JCV in the CSF is decreased. The mismatch of MET-PET and FDG-PET uptake may be useful for the early diagnosis of PML, although these examinations cannot be performed in every hospital.
